search
Back to results

Study to Evaluate the Performance of CardiacSense PPG Sensor

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Study Procedure for Participants That Were Not in the Driving Group
Study Procedure for Participants That Were Included in the Driving Group
Sponsored by
CardiacSense Ltd.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring Cardiology

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age of eighteen to eighty-five (18-85) years
  • Ability and willing to sign informed consent form
  • For subjects in groups other than Heart Arrhythmias- Self-declared not to be diagnosed with any arrhythmia
  • Compliance with hair, age, BMI skin and heart arrhythmia variables as defined above

Exclusion Criteria:

  • Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints.
  • Subject with low perfusion indicated by the watch
  • Pregnant or breastfeeding woman (women of child-bearing potential must have a negative pregnancy test within screening period).

Sites / Locations

  • Tel Aviv Sourasky Medical Center

Outcomes

Primary Outcome Measures

PPG individual peak detection
Comparison of CardiacSense1 PPG individual peak detection to the corresponding recorded activity of an FDA-cleared ECG Holter, on a beat-by-beat basis.
PPG and Holter ECG signals correlation
Evaluation of the correlation between PPG signals and Holter ECG signals with respect to R-R signal intervals.

Secondary Outcome Measures

signal intensity under different conditions
Examination of PPG signal optic parameters (LED current, LED intensity) and signal intensity under different conditions.
Adverse events
Rate of Adverse events related or unrelated to the study device.

Full Information

First Posted
April 16, 2020
Last Updated
April 16, 2020
Sponsor
CardiacSense Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04353453
Brief Title
Study to Evaluate the Performance of CardiacSense PPG Sensor
Official Title
A Prospective, Single-Center, Controlled Study to Evaluate the Performance of CardiacSense PPG Sensor in the CardiacSense1 Device
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
February 19, 2018 (Actual)
Primary Completion Date
March 18, 2019 (Actual)
Study Completion Date
March 18, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CardiacSense Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
study to evaluate the performance of the CardiacSense1's embedded PPG under different environmental and physical conditions
Detailed Description
The clinical study is a Prospective, Open, Single-Center, and Controlled Study to Evaluate the Performance of a PPG sensor in the CardiacSense1 device. The CardiacSense1 is a wrist worn device designed to detect atrial fibrillation (AF). The AF detection of the device is based on a portable photoplethysmograph (PPG) sensor that is designed for continuous heart rate monitoring. The photoplethysmograph is a noninvasive circulatory signal related to the pulsatile volume of blood in the tissue. Twenty (20) subjects (female and male) that do not suffer from atrial defibrillation and additional four (4) patients who are diagnosed as suffering from atrial fibrillation will be enrolled to the study. Comparison of CardiacSense1 PPG individual peak detection to the corresponding recorded activity of an FDA-cleared ECG Holter, on a beat-by-beat basis will be performed on the following conditions: All subjects will be exposed to 45 minutes of indoor standard office fluorescent light and 45 minutes to outdoor sunlight during mid-day. In addition, Subjects will be asked to walk for 1 minute once every 10 minutes and will be exposed to an indoor environment of 22±3 - 28±3 degree Celsius for 45 minutes and outdoor temperature of at least 15 degree Celsius, on the other 45 minutes. 4 Subjects will be tested in the following conditions: driving a car for 30 minutes; High wrist hair density subjects; Two subjects 65 y/o or older, two subjects 30 y/o or younger; Two subjects with BMI below 18.5 (underweight) and two subjects with BMI over 30 (Obesity); Two subjects with skin type 6 (Fitzpatrick) and two subjects with skin type 5; Four subjects with diagnosed persistent atrial fibrillation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
Cardiology

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Study Procedure for Participants That Were Not in the Driving Group
Intervention Description
Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition: Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor
Intervention Type
Device
Intervention Name(s)
Study Procedure for Participants That Were Included in the Driving Group
Intervention Description
Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition: Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor
Primary Outcome Measure Information:
Title
PPG individual peak detection
Description
Comparison of CardiacSense1 PPG individual peak detection to the corresponding recorded activity of an FDA-cleared ECG Holter, on a beat-by-beat basis.
Time Frame
90 Minutes
Title
PPG and Holter ECG signals correlation
Description
Evaluation of the correlation between PPG signals and Holter ECG signals with respect to R-R signal intervals.
Time Frame
90 Minutes
Secondary Outcome Measure Information:
Title
signal intensity under different conditions
Description
Examination of PPG signal optic parameters (LED current, LED intensity) and signal intensity under different conditions.
Time Frame
90 minutes
Title
Adverse events
Description
Rate of Adverse events related or unrelated to the study device.
Time Frame
90 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age of eighteen to eighty-five (18-85) years Ability and willing to sign informed consent form For subjects in groups other than Heart Arrhythmias- Self-declared not to be diagnosed with any arrhythmia Compliance with hair, age, BMI skin and heart arrhythmia variables as defined above Exclusion Criteria: Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints. Subject with low perfusion indicated by the watch Pregnant or breastfeeding woman (women of child-bearing potential must have a negative pregnancy test within screening period).
Facility Information:
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
62431
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD is not available to other researchers

Learn more about this trial

Study to Evaluate the Performance of CardiacSense PPG Sensor

We'll reach out to this number within 24 hrs